Modified-release nicotinamide for the treatment of hyperphosphataemia in haemodialysis patients: 52-week efficacy and safety results of the phase 3 randomized controlled NOPHOS trial

BACKGROUND: We previously reported that modified-release nicotinamide (NAMR) was superior to placebo in reducing serum phosphate concentrations over 12 weeks in a large cohort of haemodialysis patients with hyperphosphataemia. Here we report outcomes after 52 weeks of treatment. METHODS: NOPHOS was...

Descripción completa

Detalles Bibliográficos
Autores principales: Ketteler, Markus, Wiecek, Andrzej, Rosenkranz, Alexander R, Ose, Claudia, Rekowski, Jan, Lorenz, Horst, Hellmann, Burkhard, Karus, Michael, Ruhmann, Michaela, Ammer, Richard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10064978/
https://www.ncbi.nlm.nih.gov/pubmed/35751625
http://dx.doi.org/10.1093/ndt/gfac206

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10064978/
https://www.ncbi.nlm.nih.gov/pubmed/35751625
http://dx.doi.org/10.1093/ndt/gfac206

Ejemplares similares